Sign in
CompletedPhase 3

Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients

Key facts

Who runs it
AO GENERIUM
Where
Russia13 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
160 people enrolled
Started
28 Mar 2022
Ended
3 Apr 2024
Type of study
Interventional
Treatments tested
  • GNR-069
Record updated
21 June 2024

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (4)Hide the full registry criteria

Who can take part

  • Completion of participation in the study RMP-ITP-III while maintaining the clinical effectiveness of romiplostim therapy

Who cannot take part

  • Hypersensitivity to the components of the study drug or E. Coli proteins
  • Any diseases and conditions that, in the opinion of the Investigator, may hinder the patient's participation in the study
  • Pregnancy or breastfeeding

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

It is a phase III extension study to assess safety and immunogenicity of long-term therapy with GNR-069 in patients with idiopathic thrombocytopenic purpura

The group in the trial

  • GNR-069Treatment being tested

    Weekly subcutaneous injections of GNR-069 in the individually titrated dose.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Extension Study of Long-term Safety and Immunogenicity of GNR-069 Patients With Idiopathic Thrombocytopenic Purpura Who Completed Phase 3 RMP-ITP-III Clinical Trial
Record updated
21 June 2024